Tonix Pharma net loss improves in FQ4

|About: Tonix Pharmaceuticals Hold... (TNXP)|By:, SA News Editor

Tonix Pharmaceuticals (TNXP) FQ4 results: Revenues: $0; R&D Expense: $4.9M (-48.4%); SG&A: $2.6M (-33.3%); Net Loss: ($7.5M) (+44.0%); Loss Per Share: ($2.08) (+73.9%).

2016 results: Revenues: $0; R&D Expense: $28.5M (-19.7%); SG&A: $10.4M (-18.1%); Net Loss: ($38.8M) (+19.3%); Loss Per Share: ($15.41) (+46.2%); Quick Assets: $26.1M (-39.3%).

No guidance given.

Shares are up 2% premarket.